Contineum Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended September 30, 2026, none of our officers or directors adopted orterminated any such trading arrangements except as set forth below:
| Name (Title) | Action Taken(Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Carmine Stengone(President and Chief Executive Officer) | Adoption(August 20, 2026) | Rule 10b5-1 trading arrangement* | Sale | Until November 30, 2027, or such earlier date upon which all transactions are completed or expire without execution | Up to 290,000 shares |
| Peter Slover(Chief Financial Officer) | Adoption(August 15, 2026) | Rule 10b5-1 trading arrangement* | Sale | Until December 18, 2027, or such earlier date upon which all transactions are completed or expire without execution | Up to 56,160 shares |
| Timothy Watkins, M.D., M.Sc.(Chief Medical Officer and Head of Development) | Adoption(August 21, 2026) | Rule 10b5-1 trading arrangement* | Sale | Until December 31, 2027, or such earlier date upon which all transactions are completed or expire without execution | Up to 43,400 shares |
| John Healy(General Counsel and Corporate Secretary) | Adoption(August 19, 2026) | Rule 10b5-1 trading arrangement* | Sale | Until November 30, 2027, or such earlier date upon which all transactions are completed or expire without execution | Up to 65,002 shares |
- Intended to satisfy the affirmative defense of Rule 10b5-1(c)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.